The most common polycythemia vera therapeutics is having frequent blood withdrawals, using a needle in a vein (phlebotomy). This decreases the blood volume and reduces the number of excess blood cells. However, there is no cure for polycythemia vera, the treatment focuses on reducing the risk of complications and may also ease the signs and symptoms. Polycythemia vera is a type of blood cancer characterized by an increase in number of red blood cells in the bloodstream acquired from various sources.
It causes bone marrow to make too many red blood cells. These excess cells thicken the blood, slowing its flow, which may cause serious problems, such as blood clots. Polycythemia Vera is a cancer where extra blood cells in the bloodstream can cause many health issues. It affects slightly more men than women. According to the National Organization for Rare Disorders, the disorder is estimated to affect around 44 to 57 per 100,000 people in the U.S. It occurs most often in individuals more than 60 years old, but can affect individuals of any age.
According to Coherent Market Insights, Polycythemia Vera Therapeutics Market is estimated to be valued at US$ 1,115.9 million in 2021 and is expected to exhibit a CAGR of 4.5% over the forecast period (2021-2028).
Although it is a rare disease, there is an increasing demand for safe and effective polycythemia vera therapeutics in the world. In November 2021, the Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft (Besremi, PharmaEssentia Corporation) injection to treat adults with polycythemia vera, a blood disease that causes the overproduction of red blood cells. The excess cells thicken the blood, slowing blood flow and increasing the chance of blood clots. This medicine helps slow the production of red blood cells.
Moreover, the most common drug used to treat polycythemia vera is hydroxyurea (Hydrea, Droxia). This medicine helps slow the production of red blood cells. Some people with PV take aspirin every day because it helps thin the blood. While, hydroxyurea is a cancer drug that helps lower the number of red blood cells and platelets. Patients who do not respond to hydroxyurea are treated with ruxolitinib (jakafi) or busulfan. At times a low dose of aspirin, allopurinol and antihistamines are also preferred for polycythemia vera therapeutics.